Status:
SUSPENDED
The Safety of Transdermal Nicotine Immediately Following an Acute Coronary Syndrome
Lead Sponsor:
Sir Mortimer B. Davis - Jewish General Hospital
Collaborating Sponsors:
Canadian Tobacco Control Research Initiative
Conditions:
Smoking Cessation
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Continuing to smoke after having a heart attack greatly increases the risk of death and cardiac illness. The nicotine patch is a commonly used pharmacotherapy for smoking cessation and has great poten...
Detailed Description
Objective The STADIA Pilot Study will be used to evaluate the feasibility of conducting a three-year multi-centre trial investigating the long-term safety and efficacy outcomes associated with transd...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Current smoker, ≥ 10 cigarettes per day, on average, for the past year
- Suffered an enzyme-positive ACS (Troponin T, Troponin I, or CK-MD) and planned hospitalization of ≥ 48 hours
- Motivated to quit smoking
Exclusion
- Current use of any medical therapy for smoking cessation
- History of alcohol or controlled substance abuse
- History of severe dermatitis
- Current diagnosis of unstable psychiatric illness requiring medication
- Suffered an ACS as a complication of a hospitalization for a different condition (i.e. postoperatively)
- Pregnancy or lactation
- Likely to be unavailable for follow-up
- Unable to read and understand English or French
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2009
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00990197
Start Date
June 1 2005
End Date
December 1 2009
Last Update
October 6 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SMDB Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2